If you live in the Fort Lauderdale area, received Depo-Provera injections, and were later diagnosed with a meningioma, you may be able to join the growing federal litigation against Pfizer, and several Fort Lauderdale Depo-Provera lawsuit lawyers in Broward County are accepting these cases on a contingency-fee basis. The cases are consolidated as a multidistrict litigation in Florida, and the first bellwether trial is scheduled for December 7, 2026.1
Who Qualifies to File a Claim
Not every woman who used Depo-Provera has a case. Attorneys handling these claims generally look for four things:
- A confirmed meningioma diagnosis, typically verified by MRI or CT imaging.
- At least two injections of brand-name Depo-Provera, Depo-SubQ Provera 104, or an authorized generic version (manufacturers include Pfizer, Greenstone, and Pharmacia & Upjohn, among others) after the drug’s 1992 FDA approval.
- Generally at least one year of use. Research shows the risk climbs sharply with longer exposure.
- The meningioma developed after Depo-Provera use began. A pre-existing brain tumor, or a genetic condition independently linked to tumor development such as Neurofibromatosis type 2, can complicate or disqualify a claim.
Once a case is filed in the MDL, the plaintiff has 120 days to submit a proof-of-use and injury questionnaire backed by medical records confirming the injections, imaging showing the meningioma, pathology reports, and records of any surgical or radiation treatment.
A separate class action pending in the U.S. District Court for the Western District of Pennsylvania covers women who used Depo-Provera but have not been diagnosed with a meningioma. That case seeks funding for medical monitoring, including MRIs and neurological evaluations, rather than damages for a specific injury.
Florida Filing Deadlines You Need to Know
Florida’s statute of limitations for product liability personal injury claims is four years under Florida Statutes Section 95.11(3)(d).1 The clock starts on the date the injury was discovered, or reasonably should have been discovered, under Florida’s discovery rule.
For many Depo-Provera claimants, the discovery rule may extend the filing window because the link between the drug and meningioma was not widely recognized until a large study appeared in the British Medical Journal in March 2024. There is, however, some unsettled ground. A 2023 legislative change cut Florida’s general negligence statute of limitations from four years to two, and no Florida court has yet ruled on whether that shorter period reaches product liability claims, which have historically run on the four-year timeline.
Florida also imposes a 12-year statute of repose for products with an expected useful life of 10 years or less, measured from the date the product was first delivered to a non-commercial purchaser. Exceptions exist where the manufacturer had actual knowledge of a defect and concealed it, or where the claimant used the product within the repose period but the injury manifested afterward.
Because of these overlapping deadlines and the open legal question about which limitations period applies, waiting is the wrong instinct. Talk to an attorney early.
Why Women Are Suing Pfizer
The core allegation is that Pfizer knew or should have known that Depo-Provera increased the risk of meningioma, a tumor that forms in the membranes surrounding the brain and spinal cord, and failed to warn patients and doctors in the United States for years. The typical claims include failure to warn, negligence in designing and marketing a higher-dose injection when a lower-dose alternative existed, misleading marketing that understated neurological risks, and strict liability.
Two studies drove the litigation. A March 2024 study in the British Medical Journal found women who used injectable medroxyprogesterone acetate for at least a year had a 5.6-fold increased risk of intracranial meningioma compared with non-users. A September 2025 JAMA Neurology study by researchers at Cleveland Clinic and Case Western Reserve University reviewed records from more than 61 million women across 68 U.S. healthcare organizations and found Depo-Provera users had a 2.43-fold higher risk, with the greatest danger in women who used the drug for more than four years or started injections after age 31. The same study found no elevated meningioma risk for combined oral pills, IUDs, progestin-only pills, or subdermal implants.
The labeling history matters to these claims. Depo-Provera’s U.S. label carried no meningioma warning for decades. Pfizer applied to the FDA to add one in February 2024. The FDA initially denied the request, Pfizer resubmitted an amended application in June 2025, and the FDA approved the updated label in December 2025. The new label states that “cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use,” advises monitoring, and contraindicates the drug for patients with a current or prior meningioma. Warnings had already been added in Canada and by the European Medicines Agency in 2024. Plaintiffs point to that gap as central to the failure-to-warn case.
Reported injuries include chronic headaches, vision impairment or blindness, seizures, cognitive decline, memory loss, personality changes, and permanent brain damage, often after brain surgery, radiation therapy, and continuing medical monitoring.
What a Case Could Be Worth
No Depo-Provera settlements have been reached, so any figure is a projection rather than a benchmark. Legal analysts have offered preliminary ranges based on injury severity and comparable pharmaceutical litigation:
- Severe cases involving Grade II or III meningiomas, extensive surgery, radiation, or permanent neurological damage: roughly $300,000 to $1,000,000 or more.
- Moderate cases involving Grade I meningiomas requiring surgical removal with partial recovery and ongoing symptoms: roughly $150,000 to $300,000.
- Smaller tumors managed through monitoring or minimal intervention: roughly $75,000 to $200,000.
Case value tends to rise with younger age at exposure, longer duration of use (especially beyond three years), post-surgical complications, and evidence that Pfizer knew of international warnings while the U.S. label went unchanged. A broader study of meningioma litigation, not limited to Depo-Provera, found settlements averaged roughly $868,000 and trial verdicts averaged $3.4 million.
Where the Litigation Stands
The Depo-Provera cases are not a class action. They are consolidated as MDL No. 3140 in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers, established by the U.S. Judicial Panel on Multidistrict Litigation on February 7, 2025.1 In an MDL, each plaintiff keeps a separate case; the grouping speeds up pretrial work, but every claim is judged on its own medical history, duration of use, tumor characteristics, and losses.
As of June 2026, pending federal cases were estimated at roughly 3,500 to more than 5,500, with about 650 new lawsuits added each month. State court filings include roughly 340 in Delaware, 119 in New York, 91 in California, and 72 in Minnesota, with additional cases in Pennsylvania, Illinois, and Connecticut.
Five bellwether cases have been selected to test the claims: Blonski v. Pfizer, Schmidt v. Pfizer, Toney v. Pfizer, Valera-Arceo v. Pfizer, and Wilson v. Pfizer. The first is set for December 7, 2026. That trial, along with a pending ruling on Pfizer’s federal preemption motion and decisions on expert testimony, will heavily shape whether and how the thousands of remaining cases resolve.
Fort Lauderdale-Area Firms Taking These Cases
Several Broward County and Florida-based firms are actively accepting Depo-Provera meningioma claims.
Chalik & Chalik Injury Lawyers is a personal injury firm based in Plantation, founded by Jason and Debi Chalik in 2003. The firm takes Depo-Provera cases on contingency and has a track record in product liability litigation, including a reported $22.1 million settlement for a catastrophic brain injury caused by a defective product. It represents plaintiffs who received at least two Depo-Provera injections and have a confirmed meningioma diagnosis, and it identifies Pfizer and authorized generic manufacturers as potential defendants.
The Law Offices of Jason Turchin, based in Weston, handles Depo-Provera brain tumor claims on contingency and offers free consultations around the clock. The firm focuses on product liability and pharmaceutical injury litigation and evaluates cases based on multiple doses followed by a meningioma diagnosis.
Morgan & Morgan has attorneys licensed in Florida and operates nationwide. The firm offers free case evaluations on a contingency basis and reviews cases involving at least six months of continuous Depo-Provera use followed by a meningioma diagnosis.
How the Fee Arrangement Works
The standard arrangement across firms handling this litigation is a contingency fee. You pay nothing upfront, and the attorney takes an agreed percentage of any recovery. If there is no recovery, there is no fee. Most firms offer a free initial consultation to review your medical history, confirm your dose count and diagnosis, and decide whether your case fits the MDL criteria.
Bring what you have to that first call: dates and providers for your Depo-Provera injections, imaging and pathology reports for the meningioma, and records of any surgery, radiation, or ongoing treatment. The stronger the documentation at intake, the faster a firm can move on the 120-day proof-of-use requirement once your case is filed.